238 related articles for article (PubMed ID: 19968833)
1. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study.
Lee MS; Song HC; An H; Yang J; Ko YH; Jung IK; Joe SH
Psychiatry Clin Neurosci; 2010 Feb; 64(1):19-27. PubMed ID: 19968833
[TBL] [Abstract][Full Text] [Related]
2. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Yuan HN; Wang CY; Sze CW; Tong Y; Tan QR; Feng XJ; Liu RM; Zhang JZ; Zhang YB; Zhang ZJ
J Clin Psychopharmacol; 2008 Jun; 28(3):264-370. PubMed ID: 18480682
[TBL] [Abstract][Full Text] [Related]
3. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
[No Abstract] [Full Text] [Related]
5. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
6. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
Parsanezhad ME; Alborzi S; Jahromi BN
Int J Fertil Womens Med; 2002; 47(6):272-7. PubMed ID: 12570169
[TBL] [Abstract][Full Text] [Related]
7. [The assessment of the mental state of patients during simultaneous treatment with psychotropic drugs, antipsychotics included, and bromocriptine].
Barszcz Z; Mucha S; Rabe-Jabłońska J
Psychiatr Pol; 2008; 42(4):595-607. PubMed ID: 19189603
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine?
Smith S
J Reprod Med; 1992 Aug; 37(8):737-40. PubMed ID: 1359137
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
10. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
11. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
13. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
Lombertie ER; Durelle G; Fuseau A
Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
16. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Eklund K; Forsman A
Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
[TBL] [Abstract][Full Text] [Related]
17. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
18. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
19. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
20. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
